Cargando…
Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
BACKGROUND: Vascular stiffening, a risk factor for cardiovascular disease, is accelerated, particularly in women with obesity and type 2 diabetes. Preclinical evidence suggests that dipeptidylpeptidase-4 (DPP-4) inhibitors may have cardiovascular benefits independent of glycemic lowering effects. Re...
Autores principales: | Manrique, Camila, Habibi, Javad, Aroor, Annayya R., Sowers, James R., Jia, Guanghong, Hayden, Melvin R., Garro, Mona, Martinez-Lemus, Luis A., Ramirez-Perez, Francisco I., Klein, Thomas, Meininger, Gerald A., DeMarco, Vincent G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938903/ https://www.ncbi.nlm.nih.gov/pubmed/27391040 http://dx.doi.org/10.1186/s12933-016-0414-5 |
Ejemplares similares
-
Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice
por: Aroor, Annayya R., et al.
Publicado: (2017) -
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
por: Aroor, Annayya R., et al.
Publicado: (2018) -
Dipeptidyl Peptidase-4 Inhibition Ameliorates Western Diet–Induced Hepatic Steatosis and Insulin Resistance Through Hepatic Lipid Remodeling and Modulation of Hepatic Mitochondrial Function
por: Aroor, Annayya R., et al.
Publicado: (2015) -
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
por: Habibi, Javad, et al.
Publicado: (2017) -
Vascular stiffness in insulin resistance and obesity
por: Jia, Guanghong, et al.
Publicado: (2015)